The CHA 2 DS 2 VASc score is a clinical risk stratification tool which estimates the risk of stroke and thromboembolism in non-valvular atrial fibrillation (AF). We aimed to establish the value of this score for risk evaluation in patients with non-valvular AF and valvular heart disease.
Introduction
The risk of stroke and thromboembolism (TE) is substantially increased in patients with atrial fibrillation (AF) but this risk is not homogeneous and can be estimated in individual patients using the CHA 2 DS 2 VASc score. 1 -3 Patients with AF and CHA 2 DS 2 VASc score ¼ 0 have a very low annual risk of stroke/TE events. 4, 5 The studies which evaluated the CHA 2 DS 2 VASc score have largely studied patients with 'non-valvular AF' whether paroxysmal, persistent, or permanent. 6 Current treatment guidelines have focused on 'non-valvular' AF, where patients with a CHA 2 DS 2 VASc score of ≥2 are recommended oral anticoagulation, whether as a Vitamin K antagonist (VKA) or a novel oral anticoagulant. 7, 8 Patients with 'valvular' AF, as defined in the 2012 ESC guidelines (that is, those with a valvular prosthesis or rheumatic mitral disease) should receive anticoagulation regardless of the CHA 2 DS 2 VASc score, with VKA therapy being recommended. 8 The presence of a mechanical or biological mitral, but also aortic, valvular prosthesis is considered to be an independent risk factor of TE events in AF patients. 9, 10 Similarly, patients with AF and a background of rheumatic fever and a mitral stenosis (MS) are also at high risk of TE. 9 -11 Nonetheless, there are limited data on the risk of stroke/thromboembolic complications in AF patients with valvular heart disease, other than those with valvular prosthesis or rheumatic mitral valve disease. However, these patients may account for 15-40% of all AF patients. 12 Such valve diseases may worsen left atrial dilation, contribute to a hypercoagulable state, and possibly increase the risk of stroke. 13 In the present study, we aimed to establish the value of the CHA 2-DS 2 VASc score for stroke/TE risk evaluation in patients with 'nonvalvular AF' and valvular heart disease. We tested the hypothesis that the CHA 2 DS 2 VASc score was a good risk stratification scheme even in AF patients with valvular heart disease.
Methods

Study population
Between January 2000 and December 2010, 8962 patients seen in the Cardiology department in our institution with a diagnosis of AF were identified. The regional university hospital of Tours serves 400 000 inhabitants and is the only public institution in an area of about 4000 km 2 . The information for each patient was extracted from computerized data of hospitalization and consultation of our institution. The local ethical committee of our institution was consulted and approved this study. The informed consent of patients was deemed unnecessary for our analyses since this is a retrospective analysis of a single centre cardiology department.
The CHA 2 DS 2 VASc score, which has been validated in non-valvular AF, was calculated for each patient: scoring 2 points for a past history of stroke/TE event and age ≥75 years ; 1 point for an age between 65 and 74 years, a history of high blood pressure, diabetes, heart failure, vascular disease (myocardial infarction, complex aortic plaque, and peripheral arterial disease), and female gender. 3, 5 The HAS-BLED bleeding risk score was also calculated for each patient, which gave one point for the following items: high blood pressure, kidney and/or liver failure, stroke, haemorrhage, labile international normalized ratio, age ≥65 years, drugs and/or alcohol. 14 
Valvular disease and categorization of patients
Based on medical history and clinical presentation, the patients included in the registry had a transthoracic or transoesophageal echocardiography during their hospitalization. Our standardized echo lab with an imaging system allows us to consult each echo report easily. Echocardiographies were most often performed by trained seniors, with experience in valvular diseases. Patients with left-sided valvular heart disease were identified. Non-significant valve disease and right-sided valvular heart disease were not included in the present analysis. 'Significant' left-sided valvular heart diseases were then classified as 'severe' or 'non'severe' based on the European Society of Cardiology (ESC) guidelines. 10 Severe mitral regurgitation (MR) was described by a vena contracta width ≥7 mm, effective regurgitant orifice area ≥40 mm 2 
Stroke and thromboembolic events
Data on stroke/TE events during follow-up until December 2010 were obtained by searching in the medical database from consultation and hospitalization reports. Information on these events during the follow-up was recorded at each time it was documented within our institution, which includes a total of four hospitals covering all medical and surgical specialties. The incidence of stroke/TE events was calculated according to the CHA 2 DS 2 VASc score. From these results, we also calculated incidence of stroke/TE events in each group assuming if all patients had not been treated with anticoagulant, based on the assumption that administration of oral anticoagulation reduced the TE events risk by 64%. 2 
Statistical analysis
The characteristics of the patients were given as percentages and means + standard deviation. Comparisons between groups were made using x 2 tests to compare categorical variables, and the Student's t-test or the non-parametric Kruskal -Wallis test where appropriate for continuous variables. A proportional hazard model was used to identify independent characteristics associated with the occurrence of an event during follow-up. Potential confounding factors were entered into the model for adjustment. The proportional hazard assumption was checked by plotting the log-log Kaplan-Meier curves. The results were expressed as hazard ratios (HR) and 95% confidence intervals (CI). Since the rate of patients treated with oral anticoagulation was not the same in the different groups of patients, we also considered the observed incidence of events in patients treated with anticoagulation and estimated the rate of events with no anticoagulation based on the assumption that effective anticoagulation was associated with a decrease of 64% in the risk of stroke/TE events. 2 We then calculated a ratio of these estimated incidences. We calculated Harrell's c-statistic with 95% CIs as a measure of model performance. C-statistics give a measure of how well the risk prediction scheme identifies patients who will have a future event.
The c-statistics were calculated and then compared with others using the DeLong test. A P-value ,0.05 was considered statistically significant. Statview 5.0 (Abacus, Berkeley CA, USA) and Medcalc 15.2 (MedCalc Software, Mariakerke, Belgium) were used for statistical analysis.
Results
The characteristics of the whole population (8962 patients, age 71 + 15 years; 38% female and 39% with permanent AF) are described in Table 1 . The mean CHA 2 DS 2 VASc score was 3.2 + 1.8 and HAS-BLED score was 1.6 + 1.1. Of these patients, 57% received warfarin and 35% were treated by an antiplatelet agent. Among the 8962 patients, MR was diagnosed in 917 patients (10%), MS in 124 patients (1%), AR in 414 patients (5%), and AS in 555 patients (6%) ( Table 1) 
1017 (14) 149 (23) 3 (7) 22 (13) 59 (18) 48 (13) ,0.0001
Coronary artery bypass grafting, n (%)
375 (5) 44 (7) 3 (7) 9 (5) 21 (6) 14 (4) 0.33
Pacemaker or implantable cardioverter defibrillator, n (%)
1268 (17) 151 (23) 5 (11) 22 (13) 41 (12) 45 (12) ,0.0001 (41) 300 (46) 19 (43) 80 (48) 172 (51) 145 (39) 0.0003
Previous ischaemic stroke, n (%)
614 (8) 50 (8) 4 (9) 16 (10) 29 (9) 25 (7) 0.86
Renal insufficiency, n (%) 584 (8) 100 (15) 5 (11) 19 (11) 53 (16) 47 (13) ,0.0001
Diabetes mellitus, n (%) 1102 (15) 122 (19) 13 (30) 21 (13) 79 (24) 49 (13) ,0.0001
Chronic obstructive pulmonary disease, n (%)
764 (10) 70 (11) 4 (9) 20 (12) 46 (14) 47 (13) MR were those with the highest CHA 2 DS 2 VASc scores, while those with MS and at a less extent those with MR were more likely to be treated with oral anticoagulation. After exclusion of 909 patients with valvular AF (9%), 8053 patients were studied and categorized into Group 1 'no valve disease' (n ¼ 6851; 85%) and Group 2 'valve disease' with neither rheumatic MS nor valve prothesis (n ¼ 1202; 15%) ( Table 2) . In group 2, 61% of the patients had MR, 24% had AR, and 32% had AS (Figure 1) .The number of patients with a history of stroke/TE event was very similar in the two patient groups. Patients in Group 2 were significantly older; more frequently had heart failure, coronary artery disease and renal failure, as well as a left-ventricular ejection fraction ≤45%.
Follow-up and TE events
After follow-up of 868 + 1043 days, 627 stroke/TE events (521 strokes and 106 other systemic TE events) were recorded. Figure 2 shows the event-free curves for stroke/TE events in the 2 groups. Compared with those in Group 1 with non-valvular AF, patients in Group 2 had a significantly higher risk of these events: HR 1.39 (95% CI 1.14-1.69, P ¼ 0.001) in univariate analysis and after adjustment on oral anticoagulation (OAC) and antiplatelet agent (APA) use. Based on echocardiography, the severity of valve disease was not significantly associated with the occurrence of more stroke/TE events neither in univariate analysis (HR 1.12, 95% CI 0.78 -1.61, P ¼ 0.53) nor after adjustment on OAC and APA use ( Figure 3) .
Results of the univariate and multivariable analyses for the prediction of stroke/TE events in our cohort are in Table 3 . In univariate analysis, the risk of stroke/TE events was particularly increased (with statistical significance) in AF patients with AR and in those with AS. Oral anticoagulation was significantly associated with a lower risk of stroke/TE events (HR 0.84, 95% CI 0.72-0.99). The model for adjustment in the multivariable analysis included (i) age and gender, (ii) CHA 2 DS 2 VASc score and HASBLED score, which both cover the main comorbidities considered to be relevant in AF patients for risk stratification of thromboembolic events (many possible confounders with significant differences in Tables 1 and 2 being included in at least one these 2 scores), (iii) a set of parameters related to the type and severity of valve diseases, (iv) a set of parameters which were related to the type of atrial arrhythmia and pattern of AF, and therapy. In multivariable analysis, increasing age and increasing CHA 2-DS 2 VASc score were significantly associated with a higher risk of these events. The increased risk of stroke/TE events in patients from Group 2 (compared with those from Group 1) did not reach statistical significance (HR 1.24, 95% CI 0.84-1.83). The severity of valve disease was not independently associated with a higher risk of stroke/TE events.
CHA 2 DS 2 VASc score and rate of thromboembolism events
The rate of events per year increased with increasing CHA 2 DS 2-VASc score. For Group 1, the rate of events was 0.87%/year when CHA 2 DS 2 VASc score was 0 -1, rising to 9.67%/year when score was ≥6. For patients in Group 2, similar finding were evident with a rate of stroke/TE events increasing from 0.90%/year with a CHA 2-DS 2 VASc score 0 -1 to 11.07%/year when CHA 2 DS 2 VASc score was ≥6.
As rate of patients treated with oral anticoagulation was not the same in the two groups, we made the assumption that effective anticoagulation was associated with a decrease of 64% in the risk of stroke/TE events. 2 When annual incidence of embolism was estimated if none of the patients have been treated with oral anticoagulation, there was also an increase in the rates of events depending on CHA 2 DS 2 VASc score ( Table 5 . There were no statistical differences for c-statistic neither in the two groups of AF patients nor in patients treated or untreated with VKAs.
Discussion
In this study, we have shown for the first time that there is an increased embolic risk in so called 'non-valvular AF' patients with valve disease compared with those without valve disease. Importantly, a higher CHA 2 DS 2 VASc score was likely to explain the increased risk in these patients and should remain the main reason to decide whether OAC is needed for stroke prevention. The CHA 2 DS 2 VASc score had a similar predictive value for TE in these two groups of non-valvular AF patients.
In this study, patients with left-valvular disease accounted for 22% of all AF patients. This figure is consistent with other international registries reporting rates of 21%. 12 We found that AF patients with a left valve condition (other than MS or valve prothesis) had a higher risk of stroke/TE events than those with no such condition, while these patients are all considered to have 'non-valvular AF' in most recent guidelines. Our study is to our knowledge the first comprehensive analysis to report that patients with 'non-valvular AF and valve disease' significantly had an increased TE risk compared with other patients with 'non-valvular AF and no valve disease'. Many studies have suggested that the presence of MR with AF may play a role in the occurrence of TE events. 15, 16 Mild and moderate MR might increase the TE risk 17 in contrast to severe MR which might have a putative protective effect. 18, 19 The proposed mechanism would be an increase in atrial emptying and reduced intraatrial stasis, but these suggestions remain controversial. Our study does not allow do draw firm conclusion on this point although 61% of the AF patients in Group 1 with valve disease had MR. However, neither MR nor severity of valve disease was associated with a higher risk of stroke/TE events on multivariable analysis. Thromboembolism events related to aortic valve disease are less common than those associated with a mitral disease. The precise physiopathology of stroke in a patient with calcified AS is sometimes difficult to establish. There were 32% of the patients with AS in our group of AF patients with valve disease (18% with non-severe AS and 14% with severe AS). In current guidelines, anticoagulation is not indicated when there is no AF.
7,10 However, silent AF might be responsible for some TE events in addition to atherosclerosis or calcific microemboli in patients with valve diseases. 20 This may also explain the occurrence of acute cerebral injury within 2-3 days after a procedure of transcatheter aortic valve implantation. 20, 21 In our study, patients with AS were older, more frequently had comorbidities, and therefore had a higher CHA 2 DS 2 VASc risk score. This probably contributed to the increased risk of stroke/TE events for patients in the group with valve disease. To our knowledge, there is no relationship between AR and the risk of TE events in patients with AF. In our study, this condition did not seem to be predictive of stroke/TE events. Finally, it is noteworthy that the severity of valvular disease was not predictive of stroke/TE events in our analysis, and this has not been previously reported on such a large scale.
Ourn study confirms both the low risk of stroke/TE events in patients with low CHA 2 DS 2 VASc score and the progressive increase in the risk with increasing score up to 11%/year for a score ≥6 in 'nonvalvular AF' patients. These figures are consistent with those found in other cohorts. 22 It therefore seems valid to use the CHA 2 DS 2 VASc score in clinical practice for these AF patients since our findings may largely be explained by the more severe risk profile of patients in Group 2: older age, more heart failure with higher need of diuretics, more frequent hypertension, myocardial infarction, as well as a higher HAS-BLED score than in other groups. Considering our results of the comparison between predictive values, a major clinical implication of this work is that use of the CHA 2 DS 2 VASc score would significantly improve classification of patients at increasing risk of stroke in a similar way for non-valvular AF patients with or with no valve disease.
Limitations
This study based on a registry has the limitations of observational retrospective analysis. There were also many variables to be analysed and it is possible that remaining confounding factors interfered in the statistical analyses. Particularly, the risk and benefit associated with each antithrombotic therapy should be interpreted very cautiously in this context. A more precise comparison between the different valve diseases was not achieved because some patients belonged to several groups. Due to constant progress in echocardiographic methods to quantify valve disease severity since the early 2000s, some of the echocardiography criteria were not widely applied in the early 2000s and all the quantitative parameters were not available for each patient. Classification of the valve disease was done according to the reported parameters at the time of the echocardiography in our laboratory with standards methods but was not retrospectively reviewed. These limitations would most probably not affect the main results due to the large patient population and the clear differences in the outcomes in the different subgroups. Finally, the natural history and symptoms of a valvular disease may lead to a specific support with valvular surgery but without prosthesis or valve replacement, and this shortcoming in analysis may not allow us drawing definite conclusions.
Conclusion
This systematic analysis in 'real life' conditions reinforces the major interest of using the CHA 2 higher CHA 2 DS 2 VASc score in these patients was likely to explain these results.
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